Evofem Biosciences, Inc. (EVFM)

Evofem Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1.49	-	-	-	2.77	7.73
Short-Term Investments	0.13	0.13	0.13	0.08	-	-
Cash & Short-Term Investments	1.62	0.13	0.13	0.08	2.77	7.73
Cash Growth	368.21%	3.15%	67.11%	-97.25%	-64.19%	-84.19%
Accounts Receivable	0.56	12.48	9.83	5.74	1.13	6.45
Other Receivables	0.19	0.38	-	-	-	-
Receivables	0.75	12.86	9.83	5.74	1.13	6.45
Inventory	1.89	1.13	1.58	1.7	5.38	7.67
Prepaid Expenses	0.16	0.44	0.39	0.78	1.39	2.6
Restricted Cash	0.89	0.58	0.74	0.58	1.21	5.06
Other Current Assets	0.75	0.15	0.94	0.34	0.83	0.63
Total Current Assets	6.06	15.28	13.61	9.21	12.7	30.14
Property, Plant & Equipment	0.57	0.6	0.55	1.31	8.35	11.17
Other Intangible Assets	0.78	4.35	9.6	-	-	-
Other Long-Term Assets	0.04	0.04	0.04	0.04	4.12	1.2
Total Assets	7.44	20.27	23.79	10.55	25.16	42.51

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	12	13.15	16.17	17.02	14.98	10.32
Accrued Expenses	2.7	3.88	9	6.84	6.3	13.72
Short-Term Debt	18.92	21.6	15.11	14.73	39.42	81.72
Current Portion of Long-Term Debt	33.38	32.77	30.77	28.54	26.27	27.21
Current Portion of Leases	0.12	0.13	0.08	0.1	2.31	2.33
Other Current Liabilities	11.62	13.29	9.31	5.24	4.55	2.37
Total Current Liabilities	78.75	84.82	80.45	72.46	93.83	137.66
Long-Term Leases	0.03	0.05	0.01	0.01	3.13	4.42
Other Long-Term Liabilities	1.38	4.84	9.81	-	-	-
Total Liabilities	80.15	89.71	90.26	72.47	96.96	142.09

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0	-	0.02
Additional Paid-In Capital	831.88	831.86	829.03	823.04	817.37	751.26
Retained Earnings	-902.88	-897.39	-897.66	-888.7	-938.69	-860.68
Comprehensive Income & Other	-6.64	-8.82	-2.63	-0.85	49.53	5.09
Total Common Equity	-77.63	-74.34	-71.26	-66.51	-71.8	-104.32
Shareholders' Equity	-72.71	-69.44	-66.48	-61.92	-71.8	-99.58
Total Liabilities & Equity	7.44	20.27	23.79	10.55	25.16	42.51

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	52.46	54.55	45.97	43.37	71.13	115.68
Net Cash (Debt)	-50.84	-54.42	-45.84	-43.3	-68.36	-107.95
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.40	-0.01	-0.57	-0.04	-146.70	-1546.16
Filing Date Shares Outstanding	132.53	132.53	113.36	45.94	1.73	0.09
Total Common Shares Outstanding	132.53	126.69	113.36	20.01	0.98	0.09
Working Capital	-72.7	-69.54	-66.84	-63.25	-81.13	-107.52
Book Value Per Share	-0.59	-0.59	-0.63	-3.32	-72.91	-1203.63
Tangible Book Value	-78.41	-78.68	-80.85	-66.51	-71.8	-104.32
Tangible Book Value Per Share	-0.59	-0.62	-0.71	-3.32	-72.91	-1203.63
Machinery	0.13	0.13	0.73	1.23	2.17	2.15
Construction In Progress	0.4	0.4	0.43	1.16	1.57	2.41
Leasehold Improvements	-	-	-	-	3.39	3.39

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 29, 2026

Data Sources Report a data error